title: Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis.
abstract: A 59-year-old man with a 4-year history of light chain myeloma relapsing after two preceding autografts and salvage therapy with thalidomide underwent a peripheral blood stem cell (PBSC) transplant from his HLA-identical sister after conditioning with 100 mg/m2 melphalan. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine. Despite pulmonary infiltrates and sinusitis at the time of the allograft, it was decided to proceed with the transplant because the myeloma was refractory and rapidly progressive. Sputum cultures obtained 2 days before the allograft grew Aspergillus fumigatus 2 days post transplant. A fumigatus grew repeatedly on specimens obtained post transplant. Prompt hematologic recovery was seen with full donor-type chimerism. The fungal infection subsided gradually on a combination of amphotericin B lipid complex and itraconazole. A second aliquot of donor PBSC was infused electively on day +42 to induce graft-versus-myeloma. Complete remission of the myeloma was achieved by 75 days post transplant. No acute GVHD was seen. No chronic GVHD was seen at 16 weeks when he received the third PBSC infusion. He is currently alive and well in remission 9 months post transplant. This case demonstrates the safety and potential usefulness of allogeneic PBSC transplantation with reduced-intensity conditioning in patients with markedly compromised performance status.
authors.affiliation: Department of Internal Medicine, University of South Carolina, Columbia, USA.
authors.forename: S
authors.initials: S
authors.lastname: Singhal
authors.forename: A
authors.initials: A
authors.lastname: Safdar
authors.forename: K Y
authors.initials: KY
authors.lastname: Chiang
authors.forename: K
authors.initials: K
authors.lastname: Godder
authors.forename: F
authors.initials: F
authors.lastname: van Rhee
authors.forename: F
authors.initials: F
authors.lastname: Garner
authors.forename: B
authors.initials: B
authors.lastname: Foster
authors.forename: D
authors.initials: D
authors.lastname: Dubovsky
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
authors.forename: J
authors.initials: J
authors.lastname: Mehta
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications*; D020350:Graft vs Tumor Effect / Q000276:immunology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000382:microbiology / Q000628:therapy*; D014184:Transplantation, Homologous
chemical_list: D018906:Antineoplastic Agents, Alkylating; D016179:Granulocyte Colony-Stimulating Factor; D008558:Melphalan